Researchers are investigating retatrutide, a novel dual-agonist targeting both GLP-1 and GIP receptors. This compound demonstrates significant potential in promoting sustained weight reduction . Early studies https://reta263223.blognody.com/55803561/the-new-promise-for-obesity-treatment